- Home
- HYFT vs SERA Comparison
HYFT vs SERA Comparison
Compare HYFT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFT
- SERA
- Stock Information
- Founded
- HYFT 1983
- SERA 2008
- Country
- HYFT United States
- SERA United States
- Employees
- HYFT N/A
- SERA N/A
- Industry
- HYFT Biotechnology: Pharmaceutical Preparations
- SERA Precision Instruments
- Sector
- HYFT Health Care
- SERA Health Care
- Exchange
- HYFT Nasdaq
- SERA Nasdaq
- Market Cap
- HYFT 80.8M
- SERA 90.6M
- IPO Year
- HYFT 2017
- SERA 2021
- Fundamental
- Price
- HYFT $1.62
- SERA $3.69
- Analyst Decision
- HYFT
- SERA
- Analyst Count
- HYFT 0
- SERA 0
- Target Price
- HYFT N/A
- SERA N/A
- AVG Volume (30 Days)
- HYFT 614.3K
- SERA 38.1K
- Earning Date
- HYFT 12-09-2025
- SERA 11-10-2025
- Dividend Yield
- HYFT N/A
- SERA N/A
- EPS Growth
- HYFT N/A
- SERA N/A
- EPS
- HYFT N/A
- SERA N/A
- Revenue
- HYFT $18,214,531.00
- SERA $108,000.00
- Revenue This Year
- HYFT N/A
- SERA $217.92
- Revenue Next Year
- HYFT $71.78
- SERA $479.25
- P/E Ratio
- HYFT N/A
- SERA N/A
- Revenue Growth
- HYFT 18.33
- SERA 0.94
- 52 Week Low
- HYFT $0.27
- SERA $1.37
- 52 Week High
- HYFT $3.25
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- HYFT N/A
- SERA 61.46
- Support Level
- HYFT N/A
- SERA $3.20
- Resistance Level
- HYFT N/A
- SERA $3.64
- Average True Range (ATR)
- HYFT 0.00
- SERA 0.19
- MACD
- HYFT 0.00
- SERA 0.03
- Stochastic Oscillator
- HYFT 0.00
- SERA 89.70
About HYFT MindWalk Holdings Corp. Common Stock
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.